1887

Abstract

clonal group A (CGA) causes urinary tract and other extra-intestinal infections in humans. CGA is an important cause of trimethoprim/sulfamethoxazole (SXT) resistance in extra-intestinal pathogens. We examined the extent to which resistance in this area is related to CGA dissemination of from urinary tract infections (UTIs) in Mexico City. The virulence backgrounds of the isolates were also characterized. In this study, the frequency of resistance to SXT used for UTI treatment was high (56–65 %), and CGA isolates accounted for 9 of the 78 SXT-resistant isolates (11.5 %). Although all CGA isolates were found to be multidrug resistant (MDR), none of them were extended-spectrum β-lactamase-producing organisms. The prevalence of CGA among the 45 MDR isolates that we identified was 20 %, indicating that this clonal group moderately contributes to the antibiotic resistance of uropathogenic isolates in this region. Most of the nine CGA isolates carried transferable, large-size plasmids of approximately 80 to 100 kb, which were able to transfer antimicrobial resistance to J53 in mating assays. CGA isolates mainly belonged to phylogenetic groups F and D. We found no association between antimicrobial resistance and virulence-associated genes: the median virulence scores of CGA isolates were slightly higher (4.6) than those of non-CGA isolates, whether they were susceptible (3.7) or resistant (3.5) to SXT. Our results indicate that CGA is not a major contributor to the high level of resistance to SXT in this region but, instead, seems to be an important constituent of MDR isolates from UTIs.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.000389
2016-12-16
2020-01-26
Loading full text...

Full text loading...

/deliver/fulltext/jmm/65/12/1438.html?itemId=/content/journal/jmm/10.1099/jmm.0.000389&mimeType=html&fmt=ahah

References

  1. Al-Assil B., Mahfoud M., Hamzeh A. R.. 2013; First report on class 1 integrons and trimethoprim-resistance genes from dfrA group in uropathogenic E. coli (UPEC) from the Aleppo area in Syria. Mob Genet Elements3:e25204 [CrossRef][PubMed]
    [Google Scholar]
  2. Ali I., Kumar N., Ahmed S., Dasti J. I. 2014; Antibiotic resistance in uropathogenic E. coli strains isolated from non-hospitalized patients in Pakistan. J Clin Diagn Res8:1–4
    [Google Scholar]
  3. Blanco J., Mora A., Mamani R., López C., Blanco M., Dahbi G., Herrera A., Blanco J. E., Alonso M. P. et al. 2011; National survey of Escherichia coli causing extraintestinal infections reveals the spread of drug-resistant clonal groups O25b:H4-B2-ST131, O15:H1-D-ST393 and CGA-D-ST69 with high virulence gene content in Spain. J Antimicrob Chemother66:2011–2021 [CrossRef][PubMed]
    [Google Scholar]
  4. Boczek L. A., Rice E. W., Johnston B., Johnson J. R.. 2007; Occurrence of antibiotic-resistant uropathogenic Escherichia coli clonal group A in wastewater effluents. Appl Environ Microbiol73:4180–4184 [CrossRef][PubMed]
    [Google Scholar]
  5. Chen L. F., Freeman J. T., Nicholson B., Keiger A., Lancaster S., Joyce M., Woods C. W., Cook E., Adcock L. et al. 2014; Widespread dissemination of CTX-M-15 genotype extended-spectrum-β-lactamase-producing enterobacteriaceae among patients presenting to community hospitals in the southeastern United States. Antimicrob Agents Chemother58:1200–1202 [CrossRef][PubMed]
    [Google Scholar]
  6. CLSI 2012; Antimicrobial Susceptibility Testing; Twentieth Informational Supplement CLSI M100-S20-U Wayne, PA: Clinical and Laboratory Standards Institute;
    [Google Scholar]
  7. CLSI 2014; M100-S24- Performance Standards for Antimicrobial Susceptibility Testing
  8. Clermont O., Christenson J. K., Denamur E., Gordon D. M.. 2013; The Clermont Escherichia coli phylo-typing method revisited: improvement of specificity and detection of new phylo-groups. Environ Microbiol Rep5:58–65 [CrossRef][PubMed]
    [Google Scholar]
  9. Coque T. M., Novais A., Carattoli A., Poirel L., Pitout J., Peixe L., Baquero F., Cantón R., Nordmann P.. 2008; Dissemination of clonally related Escherichia coli strains expressing extended-spectrum beta-lactamase CTX-M-15. Emerg Infect Dis14:195–200 [CrossRef][PubMed]
    [Google Scholar]
  10. Da Silva G. J., Mendonça N.. 2012; Association between antimicrobial resistance and virulence in Escherichia coli. Virulence3:18–28 [CrossRef][PubMed]
    [Google Scholar]
  11. Dias R. C., Marangoni D. V., Smith S. P., Alves E. M., Pellegrino F. L., Riley L. W., Moreira B. M.. 2009; Clonal composition of Escherichia coli causing community-acquired urinary tract infections in the State of Rio de Janeiro, Brazil. Microb Drug Resist15:303–308 [CrossRef][PubMed]
    [Google Scholar]
  12. Drews S. J., Poutanen S. M., Mazzulli T., McGeer A. J., Sarabia A., Pong-Porter S., Rzayev Y., Willey B., Green K., Low D. E.. 2005; Decreased prevalence of virulence factors among ciprofloxacin-resistant uropathogenic Escherichia coli isolates. J Clin Microbiol43:4218–4220 [CrossRef][PubMed]
    [Google Scholar]
  13. Guajardo-Lara A. L., González-Martínez P. M., Ayala-Gaytán J. J.. 2009; Resistencia antimicrobiana en la infección urinaria por Escherichia coli adquirida en la comunidad. ¿Cuál Antibiótico Voy a Usar? Salud Pública Mex 51:155–158
    [Google Scholar]
  14. Guyer D. M., Radulovic S., Jones F. E., Mobley H. L.. 2002; Sat, the secreted autotransporter toxin of uropathogenic Escherichia coli, is a vacuolating cytotoxin for bladder and kidney epithelial cells. Infect Immun70:4539–4546 [CrossRef][PubMed]
    [Google Scholar]
  15. Jarlier V., Nicolas M. H., Fournier G., Philippon A.. 1988; Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Rev Infect Dis10:867–878 [CrossRef][PubMed]
    [Google Scholar]
  16. Johnson J. R., Russo T. A., Tarr P., Carlino U., Bilge S. S., Vary J. C., Stell A. L.. 2000; Molecular epidemiological and phylogenetic associations of two novel putative virulence genes, iha and iron, among Escherichia coli isolates from patients with urosepsis. Infect Immun68:3040–3047 [CrossRef][PubMed]
    [Google Scholar]
  17. Johnson J. R., Manges A. R., O′Bryan T. T., Riley L. R.. 2002; A disseminated multi-drug resistant clonal group of extraintestinal pathogenic Escherichia coli as a cause of pyelonephritis. Lancet359:2249–2251
    [Google Scholar]
  18. Johnson J. R., Owens K., Manges A. R., Riley L. W., Amee R.. 2004a; Rapid and specific detection of Escherichia coli clonal group A by gene-specific PCR. J Clin Microbiol42:2618–2622 [CrossRef][PubMed]
    [Google Scholar]
  19. Johnson J. R., Kuskowski M. A., Gajewski A., Sahm D. F., Karlowsky J. A.. 2004b; Virulence characteristics and phylogenetic background of multidrug-resistant and antimicrobial-susceptible clinical isolates of Escherichia coli from across the United States, 2000–2001. J Infect Dis190:1739–1744 [CrossRef]
    [Google Scholar]
  20. Johnson J. R., Murray A. C., Kuskowski M. A., Schubert S., Prère M. F., Picard B., Colodner R., Raz R.. Trans-Global Initiative for Antimicrobial Resistance Initiative (TIARA) Investigators 2005; Distribution and characteristics of Escherichia coli clonal group A. Emerg Infect Dis11:141–145 [CrossRef][PubMed]
    [Google Scholar]
  21. Johnson J. R., Menard M., Johnston B., Kuskowski M. A., Nichol K., Zhanel G. G.. 2009; Epidemic clonal groups of Escherichia coli as a cause of antimicrobial-resistant urinary tract infections in Canada, 2002 to 2004. Antimicrob Agents Chemother53:2733–2739 [CrossRef][PubMed]
    [Google Scholar]
  22. Johnson J. R., Johnston B., Clabots C., Kuskowski M. A., Castanheira M.. 2010; Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States. Clin Infect Dis51:286–294 [CrossRef][PubMed]
    [Google Scholar]
  23. Johnson J. R., Menard M. E., Lauderdale T. L., Kosmidis C., Gordon D., Collignon P., Maslow J. N., Andrasević A. T., Kuskowski M. A.. Trans-Global Initiative for Antimicrobial Resistance Analysis Investigators 2011; Global distribution and epidemiologic associations of Escherichia coli clonal group A, 1998-2007. Emerg Infect Dis17:2001–2009 [CrossRef][PubMed]
    [Google Scholar]
  24. Johnson J. R., Urban C., Weissman S. J., Jorgensen J. H., Lewis J. S., Hansen G., Edelstein P. H., Robicsek A., Cleary T. et al. 2012; Molecular epidemiological analysis of Escherichia coli sequence type ST131 (O25, H4) and blaCTX-M-15 among extended-spectrum-β-lactamase-producing E. coli from the United States, 2000 to 2009. Antimicrob Agents Chemother56:2364–2370 [CrossRef][PubMed]
    [Google Scholar]
  25. Karlowsky J. A., Hoban D. J., Decorby M. R., Laing N. M., Zhanel G. G.. 2006; Fluoroquinolone-resistant urinary isolates of Escherichia coli from outpatients are frequently multidrug resistant: results from the North American Urinary Tract Infection Collaborative Alliance-Quinolone Resistance study. Antimicrob Agents Chemother50:2251–2254 [CrossRef][PubMed]
    [Google Scholar]
  26. Kuhar I., Grabnar M., Zgur-Bertok D.. 1998; Virulence determinants of uropathogenic Escherichia coli in fecal strains from intestinal infections and healthy individuals. FEMS Microbiol Lett164:243–248 [CrossRef][PubMed]
    [Google Scholar]
  27. Le Bouguenec C., Archambaud M., Labigne A.. 1992; Rapid and specific detection of the pap, afa, and sfa adhesin-encoding operons in uropathogenic Escherichia coli strains by polymerase chain reaction. J Clin Microbiol30:1189–1193[PubMed]
    [Google Scholar]
  28. López-Banda D. A., Carrillo-Casas E. M., Leyva-Leyva M., Orozco-Hoyuela G., Manjarrez-Hernández ÁH., Arroyo-Escalante S., Moncada-Barrón D., Villanueva-Recillas S., Xicohtencatl-Cortes J. et al. 2014; Identification of virulence factors genes in Escherichia coli isolates from women with urinary tract infection in Mexico. Biomed Res Int2014:959206 [CrossRef][PubMed]
    [Google Scholar]
  29. Manges A. R., Johnson J. R., Foxman B., O'Bryan T. T., Fullerton K. E., Riley L. W.. 2001; Widespread distribution of urinary tract infections caused by a multidrug-resistant Escherichia coli clonal group. N Engl J Med345:1007–1013 [CrossRef][PubMed]
    [Google Scholar]
  30. Manges A. R., Dietrich P. S., Riley L. W.. 2004; Multidrug-resistant Escherichia coli clonal groups causing community-acquired pyelonephritis. Clin Infect Dis38:329–334 [CrossRef][PubMed]
    [Google Scholar]
  31. Miller J.. 1972; Experiments in Molecular Genetics Cold Spring Harbor, NY: Cold Spring Harbor Laboratory;
    [Google Scholar]
  32. Miller J.. 1992; A Short Course in Bacterial Genetics Cold Spring Harbor, NY: Cold Spring Harbor Laboratory;
    [Google Scholar]
  33. Molina-López J., Aparicio-Ozores G., Ribas-Aparicio R. M., Gavilanes-Parra S., Chávez-Berrocal M. E., Hernández-Castro R., Manjarrez-Hernández H. Á.. 2011; Drug resistance, serotypes and phylogenetic groups among uropathogenic Escherichia coli including O25-ST131 in Mexico City. J Infect Dev Ctries5:840–849
    [Google Scholar]
  34. Nys S., van Merode T., Bartelds A., Stobberingh E. E.. 2006; Antibiotic treatment and resistance of unselected uropathogens in the elderly. Int J Antimicrob Agents27:236–241 [CrossRef][PubMed]
    [Google Scholar]
  35. Ons E., Bleyen N., Tuntufye H. N., Vandemaele F., Goddeeris B. M.. 2007; High prevalence iron receptor genes of avian pathogenic Escherichia coli. Avian Pathol36:411–414 [CrossRef][PubMed]
    [Google Scholar]
  36. O'Toole G. A., Pratt L. A., Watnick P., Newman D. K., Weaver V. B., Kolter R.. 1999; Genetic approaches to study of biofilms. Methods Enzymol310:91–109[PubMed]
    [Google Scholar]
  37. Park C. H., Robicsek A., Jacoby G. A., Sahm D., Hooper D. C.. 2006; Prevalence in the United States of aac(6′)-Ib-cr encoding a ciprofloxacin-modifying enzyme. Antimicrob Agents Chemother50:3953–3955 [CrossRef][PubMed]
    [Google Scholar]
  38. Picard B., Garcia J. S., Gouriou S., Duriez P., Brahimi N., Bingen E., Elion J., Denamur E.. 1999; The link between phylogeny and virulence in Escherichia coli extraintestinal infection. Infect Immun67:546–553[PubMed]
    [Google Scholar]
  39. Ruiz J., Simon K., Horcajada J. P., Velasco M., Barranco M., Roig G., Moreno-Martínez A., Martínez J. A., Jiménez de Anta T et al. 2002; Differences in virulence factors among clinical isolates of Escherichia coli causing cystitis and pyelonephritis in women and prostatitis in men. J Clin Microbiol40:4445–4449 [CrossRef][PubMed]
    [Google Scholar]
  40. Russo T. A., Johnson J. R.. 2003; Medical and economic impact of extraintestinal infections due to Escherichia coli: an overlooked epidemic. Microbes Infect5:449–456
    [Google Scholar]
  41. Sahm D. F., Thornsberry C., Mayfield D. C., Jones M. E., Karlowsky J. A.. 2001; Multidrug-resistant urinary tract isolates of Escherichia coli: prevalence and patient demographics in the United States in 2000. Antimicrob Agents Chemother45:1402–1406 [CrossRef][PubMed]
    [Google Scholar]
  42. Sambrook J., Fritsch E. F., Maniatis T.. 1989; Molecular Cloning: A Laboratory Manual Cold Spring Harbor, NY: Cold Spring Harbor Laboratory;
    [Google Scholar]
  43. Schito G. C., Naber K. G., Botto H., Palou J., Mazzei T., Gualco L., Marchese A.. 2009; The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections. Int J Antimicrob Agents34:407–413 [CrossRef][PubMed]
    [Google Scholar]
  44. Skjøt-Rasmussen L., Olsen S. S., Jakobsen L., Ejrnaes K., Scheutz F., Lundgren B., Frimodt-Møller N., Hammerum A. M.. 2013; Escherichia coli clonal group A causing bacteraemia of urinary tract origin. Clin Microbiol Infect19:656–661 [CrossRef][PubMed]
    [Google Scholar]
  45. Stepanovic S., Vukovic D., Dakic I., Savic B., Svabic-Vlahovic M.. 2000; A modified microtiter-plate test for quantification of staphylococcal biofilm formation. J Microbiol Methods40:175–179 [CrossRef][PubMed]
    [Google Scholar]
  46. Tartof S. Y., Solberg O. D., Manges A. R., Riley L. W.. 2005; Analysis of a uropathogenic Escherichia coli clonal group by multilocus sequence typing. J Clin Microbiol43:5860–5864 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.000389
Loading
/content/journal/jmm/10.1099/jmm.0.000389
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error